上皮性卵巢癌160例预后相关因素分析
杜俊瑶1,杜振广2,常璐3,饶珺3,李联昆1
中国实用妇科与产科杂志 ›› 2014, Vol. 30 ›› Issue (6) : 475-478.
上皮性卵巢癌160例预后相关因素分析
Analysis of prognostic factors of 160 cases with epithelial ovarian cancer.
目的 探讨上皮性卵巢癌的预后相关因素及5年生存率。方法 回顾性分析2006年1月至2007年12月辽宁省肿瘤医院初治的上皮性卵巢癌患者160例的临床资料。结果 单因素分析筛选出产次、手术分期、腹膜转移、残余瘤大小、化疗疗程、铂类敏感及化疗后CA125水平与卵巢癌的预后相关(P<0.05)。以手术分期Ⅳ期患者的死亡风险为1,则Ⅰ、Ⅱ、Ⅲ期患者的死亡风险分别为0.164、0.175、0.359,95%CI分别为0.035~0.775、0.037~0.820、0.184~0.704(P<0.05);术后化疗疗程≥6个疗程患者的死亡风险为<6个疗程的0.368倍,95%CI为0.209~0.647(P<0.01);铂类不敏感患者的死亡风险为敏感的4.434倍,95%CI为2.454~8.012(P<0.01);治疗后CA125水平>35 kU/L患者的死亡风险为≤35 kU/L的2.062倍,95%CI为1.190~3.572([WTBX]P[WTBZ]=0.01)。结论 手术分期、化疗疗程、铂类敏感及化疗后CA125水平是上皮性卵巢癌的独立预后因素。
Abstract:Objective To assess prognostic factors impacted on overall survival in patients with epithelial ovarian carcinoma.Methods Totally 160 patients with stages I-IV epithelial ovarian carcinoma admitted in Liao-ning Provincial Cancer Hospital from Jan. 2006 to Dec. 2007 were analyzed by retrospective analysis.Results The prognosis of epithelial ovarian carcinomas were related to the number of labors,stage, peritoneal metastasis, the size of residues lesions, the number of courses of chemotherapy, sensitivity to platinum and the level of CA125 after 2-3 courses of chemotherapy (P<0.05).Compared with stage Ⅳ, the risk of mortality was 0.164 for stage Ⅰ(95%CI 0.035-0.775),0.175 for stage Ⅱ(95%CI 0.037-0.820),0.359 (95%CI 0.184-0.704 ) for stage Ⅲ ([WTBX]P[WTBZ]<0.05). The risk of mortality was 0.368,(95%CI 0.209~0.647) for the patients received ≥6 courses of chemotherapy,in comparison with patients received <6 courses of chemotherapy(P<0.01).The risk of mortality in the patients insensitive to platinum was 4.434 times higher than that in patients sensitive to platinum (95%CI 2.454-8.012, P<0.01). The risk of mortality in the patients of serum CA125>35 kU/L after 2-3 courses of chemotherapy was 2.062 times higher than that in patients CA125≤35 kU/L (95%CI 1.190-3.572,[WTBX]P[WTBZ]=0.01).Conclusion The major independent prognostic factor of epithelial ovarian carcinoma is stage, the number of course of chemotherapy,sensitivity to platinum and the level of CA125 after 2-3 courses of chemotherapy.
[1] 连利娟.林巧稚妇科肿瘤学[M].4版.北京:人民卫生出版社,2006:580.
[2] Bell J,Brady MF,Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study[J].Gynecol Oncol,2006,102(3):432-439.
[3] Bertelsen K,Jakobsen A,Str yer J,et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA) [J].Gynecol Oncol,1993,49(1):30-36.
[4] 黄永文,李玉洁,李孟达.Ⅱ~Ⅳ期上皮性卵巢癌术后化疗方案选择和疗程优化的探讨[J].癌症,2005,24(8):994-997.
[5] 黄啸,蔡树模,汤洁,等.综合性治疗复发性卵巢癌上皮性癌的疗效及预后分析[J].中华妇产科杂志,2004,39:602-605.
[6] Iwase H, Takada T, Iitsuka C, et al.Clinical features of long-term survivors of recurrent epithelial ovarian cancer[J].Int J Clin Oncol,2014,Mar 26. [Epub ahead of print]
[7] 周慧梅,黄慧芳,潘凌亚,等.血清CA125值的变化对判断上皮性卵巢癌疗效及预后的临床研究[J].中国实用妇科与产科杂志,2008,24(3):204-206.
[8] Van Altena AM,Kolwijck E,Spanjer MJ,et al.CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study[J].Gynecol Oncol,2010,119(2):265-269.
辽宁省博士启动基金资助(20101058)
/
| 〈 |
|
〉 |